Publications

Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

 113
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

Tags:

Previous Article

Human Schwann cell lipid dysregulation and plasma membrane perturbation in Charc...

Next Article

FerroTerminator1 as a potent therapeutic drug for MASH

Related Posts

Revisiting oligodendrocytes in amyotrophic lateral sclerosis using human multicellular stem cell models

Revisiting oligodendrocytes in amyotrophic lateral scle...

 78

Predictive value of plasma p-tau217 for Alzheimer’s dementia compared to other blood-based biomarkers

Predictive value of plasma p-tau217 for Alzheimer’s dem...

 63

Lithium deficiency and the onset of Alzheimer’s disease

Lithium deficiency and the onset of Alzheimer’s disease

 288